Licaminlimab

林卡利单抗

Report date: 2026/04/24 20:01:59

Base Information

Drug NameLicaminlimab
Drug Alias NameOCS-02ESBA-1622LME-636
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsUveitis, AnteriorDry Eye SyndromesXerophthalmia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesOculis PharmaAlcon
China Registration ClassN/A

Develop Information

Active CompaniesOculisEuropean Biotech Acquisition Corp
Inactive CompaniesNovartis Institutes For Biomedical Research IncAlcon, A Novartis CompanyAlcon
Active IndicationsDry Eye Syndromes
Inactive IndicationsUveitis, AnteriorXerophthalmia

Other Information

ATC CodeN/A
Related LinksN/A